The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
News|Articles|June 25, 2024
SLIDESHOW: Vitiligo Treatments Through Time
Author(s)Lauren Buchanan, MA, Managing Editor
The treatment of vitiligo has advanced from ancient herbal remedies to the first FDA-approved topical, paving the way for improved management and outcomes.
Advertisement
What do you think the most significant vitiligo treatments are? Do you have an interesting case to share? We would love to hear from you! Email
References
- Cunningham K, Rosmarin D. Vitiligo treatments: review of current therapeutic modalities and JAK inhibitors. Am J Clin Dermatol. 2023;24(2):165-186. doi:10.1007/s40257-022-00752-6
- Dhanik A, Sujatha N, Rai N. Clinical evaluation of the efficacy of Shvitraharakashaya and lepa in vitiligo. Ayu. 2011;32(1):66-69. doi:10.4103/0974-8520.85731
- Das A, Panda S. Use of topical corticosteroids in dermatology: an evidence-based approach. Indian J Dermatol. 2017;62(3):237-250. doi:10.4103/ijd.IJD_169_17
- Bleehen SS. The treatment of vitiligo with topical corticosteroids. Light and electronmicroscopic studies. Br J Dermatol. 1976;94 suppl 12:43-50. doi:10.1111/j.1365-2133.1976.tb02268.x
- Shenoi SD, Prabhu S. Photochemotherapy (PUVA) in psoriasis and vitiligo. Indian J Dermatol VenereolLeprol. 2014;80(6):497-504. doi:10.4103/0378-6323.144143
- Myers E, Kheradmand S, Miller R. An Update on Narrowband Ultraviolet B Therapy for the Treatment of Skin Diseases. Cureus. 2021;13(11):e19182. Published 2021 Nov 1. doi:10.7759/cureus.19182
- Lee JH, Kwon HS, Jung HM, et al. Treatment Outcomes of Topical Calcineurin Inhibitor Therapy for Patients With Vitiligo: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019;155(8):929–938. doi:10.1001/jamadermatol.2019.0696
- Post NF, Ezekwe N, Narayan VS, et al. The use of lasers in vitiligo, an overview. J EurAcad Dermatol Venereol. 2022;36(6):779-789. doi:10.1111/jdv.18005
- Toh J, Chuah S, Jhingan A, Chong W, Thng S. Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians. J Am Acad Dermatol. 2020;82(6):1517-1519. doi:10.1016/j.jaad.2020.01.035
- Rosmarin D, Passeron T, Pandya AG, et al. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022;387(16):1445-1455. doi:10.1056/NEJMoa2118828
- New long-term data from Incyte phase 3 TRuE-V program demonstrates efficacy of continued treatment with Opzelura® (ruxolitinib) cream in nonsegmental vitiligo patients. News release. Incyte. October 11, 2023. Accessed June 25, 2024.
https://investor.incyte.com/news-releases/news-release-details/new-long-term-data-incyte-phase-3-true-v-program-demonstrates
Advertisement
Related to this article
Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.
The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.
Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
Beyond Dry Skin: Rethinking Common Eczema Misconceptions
3
FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria
4
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
5